VIR — Vir Biotechnology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1706431 ·
Last close
$9.25
Market Cap
$1.58B
52W High
$14.38
52W Low
$5.32
ADV30
2,697,368
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | -200,000 | -200,000 | -104,658,000 | -96,252,000 | 1,111,855,000 | 218,866,000 | 215,819,000 |
| Jun 2026 | 238,935,000 | 238,935,000 | 73,467,000 | 80,080,000 | 1,214,806,000 | 278,729,000 | 232,313,000 |
| Mar 2026 | -41,000 | — | -132,290,000 | -125,695,000 | 1,025,585,000 | 274,161,000 | 212,820,000 |
| Dec 2025 | 63,760,000 | 63,734,000 | -47,921,000 | -42,923,000 | 1,002,823,000 | 232,185,000 | 237,547,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-141,017,000
Investing CF
$-54,097,000
Financing CF
$243,572,000
CapEx
$-804,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.26
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,339,638,000
Inventory
—
Receivables
—
ST Investments
$239,491,000
EBIT TTM
$-211,402,000
Pretax Income TTM
$-184,721,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$302,799,008
EBITDA
$-201,320,992
Free Cash Flow
$-81,924,248
Enterprise Value
$1,723,634,176
Total Cash
$458,356,992
Total Debt
$90,775,000
Shares Out
171,270,773
Trailing EPS
$-1.18
Book Value
$5.29
ROE
-21.8%
ROA
-12.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 66,520,000 | -479,510,000 | -437,987,000 | 1,002,823,000 | 237,547,000 | 765,276,000 | -391,781,000 |
| Dec 2024 | 63,712,000 | -552,170,000 | -521,960,000 | 1,398,813,000 | 248,428,000 | 1,150,385,000 | -446,352,000 |
| Dec 2023 | 39,494,000 | -670,746,000 | -615,061,000 | 1,919,060,000 | 328,824,000 | 1,590,236,000 | -778,785,000 |
| Dec 2022 | 1,580,472,000 | 833,068,000 | 515,837,000 | 2,802,088,000 | 724,125,000 | 2,077,963,000 | 1,663,253,000 |
TTM Snapshot
Revenues TTM
$303,227,000
NetIncome TTM
$-251,679,000
OpCashFlow TTM
—
Assets (Latest)
$1,214,806,000
Forward EPS
$-2.32
Max Pain — expiry 2027-01-15
max pain strike: $9.00 · spot: $9.15 · call oi: 6,313 · put oi: 421
Expected Move to 2027-01-15:
±$2.50
(27.32%) —
implied range
$6.65 –
$11.65
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALVO | Alvotech | $1.56B | $4.37 | — |
| LYCA | Lycia Therapeutics, Inc. | $1.61B | $30.92 | — |
| MESO | MESOBLAST LTD | $1.55B | $11.91 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
Vir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock Sale
2026-11-13 17:14 · Yahoo
Vir Biotechnology stock tumbles on $150M share offering
2026-11-13 14:57 · Yahoo
Sector Update: Healthcare Stocks Rise Pre-Bell Friday
2026-11-13 14:16 · Yahoo
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
2026-11-13 00:38 · Yahoo
Vir Biotechnology Announces Proposed Public Offering
2026-11-12 21:08 · Yahoo
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
2026-11-10 14:12 · Yahoo
Vir Biotechnology’s hepatitis D drug scores in Phase II and Phase III trials
2026-11-10 10:17 · Yahoo
Is Vir Biotechnology (VIR) Overvalued After Its 127% Run?
2026-11-09 20:07 · Yahoo
Vir Biotechnology (VIR) Says Its Hepatitis Delta Therapy Met All Phase 3 Endpoints
2026-11-09 19:13 · Yahoo
Vir hepatitis D drug succeeds in first pivotal study
2026-11-09 17:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.